Tech Company Financing Transactions
Entos Pharmaceuticals Funding Round
On 2/5/2025, Entos Pharmaceuticals raised $4 million in funding from California Institute for Regenerative Medicine.
Transaction Overview
Company Name
Announced On
2/5/2025
Transaction Type
Debt
Amount
$4,000,000
Round
Undisclosed
Proceeds Purpose
The funds will support the completion of IND-enabling activities for the development of ENTLEP001, a durable genetic medicine for the treatment of congenital generalized lipodystrophy (CGL).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10230 Jasper Avenue 4550
Edmonton, AB, T5J 4P6
Canada
Edmonton, AB, T5J 4P6
Canada
Phone
Website
Email Address
Overview
Entos is committed to using its Fusogenix� PLV� technology to develop cures and improve the lives of patients and their families.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Lewis
Browse more venture capital transactions:
Prev: 2/4/2025: Coolnis venture capital transaction
Next: 2/5/2025: Froda venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs